BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced an oral presentation on galeterone at the 2016 American Urological Association (AUA) Annual Meeting in San Diego. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistant prostate cancer.
The presentation, titled “Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2” (abstract number PD32-07), will be presented on Sunday, May 8, from 4:30 - 4:40 p.m. PDT in room 30DE, as part of the session, “Prostate Cancer: Advanced (including Drug Therapy) III.” The presenting author is Vincent C.O. Njar, Ph.D., Professor of Medicinal Chemistry and Pharmacology, Department of Pharmacology; Head of the Medicinal Chemistry Section, Center for Biomolecular Therapeutics; and Member of the Marlene and Stewart Greenebaum Cancer Center at the University of Maryland School of Medicine, Baltimore. Dr. Njar is a co-inventor of galeterone.
Additional information, including the presentation schedule and full abstracts, may be found at www.aua2016.org. A copy of the presentation will be available on the “Publications & Presentations” page of Tokai’s website, www.tokaipharmaceuticals.com.
About Galeterone
Galeterone is an oral small molecule that
utilizes the established pathways, including CYP17 enzyme and androgen
receptor inhibition, of the current second-generation hormonal therapies
abiraterone and enzalutamide. Galeterone also introduces a distinct
third mechanism – androgen receptor degradation – that decreases the
sensitivity of androgen receptors to androgen activity, thus leading to
reductions in tumor growth. Tokai is developing galeterone for the
treatment of patients with metastatic castration-resistant prostate
cancer (mCRPC). ARMOR3-SV, the company’s pivotal Phase 3 study of
galeterone in treatment-naive mCRPC patients whose prostate tumors
express the AR-V7 splice variant, is evaluating whether administration
of galeterone results in a statistically significant increase in
radiographic progression-free survival as compared to enzalutamide.
Tokai is also evaluating galeterone in mCRPC patients who have shown
resistance following treatment with second-generation hormonal agents.
Tokai has worldwide development and commercialization rights to
galeterone.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a
biopharmaceutical company focused on developing and commercializing
innovative therapies for prostate cancer and other hormonally driven
diseases. The company’s lead drug candidate, galeterone, is an oral
small molecule that utilizes the mechanistic pathways of current
second-generation anti-androgens, while also introducing a unique third
mechanism – androgen receptor degradation. Tokai is developing
galeterone for the treatment of patients with metastatic
castration-resistant prostate cancer. The company’s ARDA drug discovery
program is focused on the identification and evaluation of compounds
that are designed to disrupt androgen receptor signaling through
enhanced androgen receptor degradation and are targeted to patients with
androgen receptor signaling diseases, including prostate cancer. For
more information on the company and galeterone, please visit www.tokaipharmaceuticals.com.
